U.S. Influenza Market by Drug Class (Anti-viral drugs, Vaccines), Route of Administration (Oral, Parenteral, Others), Distribution Channel (Hospital pharmacies, Retail pharmacies, Others)

 

Purchase Option

$ 3000
$ 4400
$ 4600
$ 6900

The U.S. Influenza Market was valued at US$ 2.7 billion in 2021 and is expected to witness a CAGR of 16.2% over the forecast period 2022–2028 Influenza is an upper respiratory tract disease and is caused by the influenza virus. U.S. Influenza Market is mainly three types namely Influenza A, Influenza B, and Influenza C. Influenza is a communicable disease, spread through a flu cough, droplets from the infected people, sneeze or talks. The common symptoms occur in influenza patients are chills, cough, running nose, sore throat, body aches, headache, fatigue, some cases people may have vomiting and diarrhea. The complication of the disease may include ear infections, bacterial pneumonia, dehydration, sinus infections, and sometimes it leads to congestive heart failure, and asthma. Influenza commonly occurs in geriatric population and children with less than 5 years of age.  The infection may be confirmed by testing the sputum, nose, or throat for the virus. A number of rapid tests are available however polymerase chain reaction that detects the virus's RNA is more accurate. Influenza vaccines are key revenue contributor for the growth of U.S. influenza market. The U.S. influenza market is in growing phase, several international players are actively involved in the development of vaccines and drugs to treat influenza. The launch of new products, technological innovations, and approvals from U.S. Food and Drug Administration (FDA) for various drugs might fuel the growth of U.S. influenza market. For instance, Squires used both egg and cell-based technologies to offer the broadcast portfolio of influenza vaccines in the U.S. for both trivalent and quadrivalent formulations. Similarly, transformative changes in other vaccine markets, due to the entrance of expensive and innovative vaccines such as Gardasil (Merck) and Bexsero (GSK) are projected to contribute growth of the U.S. influenza market. In May 2016, Seqirus received approval from U.S. Food and Drug Administration for Flucelvax Quadrivalent, that was the first U.S. licensed cell-based quadrivalent influenza vaccine indicated for people aged four years and older. In November 2016, GSK received approval from U.S. Food and Drug Administration for flulaval Quadrivalent to include use in children aged six months or older

 

U S Influenza Market Summary

Study Period

2023-29

Base Year

2022

CAGR

16.2%

Largest Market

U.S

Fastest Growing Market

N/A
U.S. Influenza Market Dynamics

The U.S. Influenza market is growing at a significant CAGR due to rise in newborn babies, an increase in geriatric population. Increase in vaccination awareness, favorable reimbursement scenario, and rising investment by companies in research and development activities are the major factors fuelling the growth of U.S. influenza market over the forecast period. The major market players have great pipeline products, initiatives by government bodies such as WHO and CDC to control and prevent influenza, technological advancements in diagnostic tests also fuel the growth of U.S. influenza market over the forecast period. However, limited production capacity, a high level of required investment, and stringent regulatory policies for new product approvals might hamper the growth of U.S. Influenza market. Due to limitations in current technologies, the lengthy production times (approximately seven months), increase in prices of influenza diagnostic kits and reagents also hinder the U.S. Influenza market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

U S Influenza Market Segmentation

Drug Class,
    • Zanamivir
    • Oseltamivir
    • Amantadine
    • Rimantadine
    • Others
    • Interferons
  • Vaccines
    • Trivalent
    • Quadrivalent
Route of Administrat
  • Oral
  • Parenteral
  • Others
Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Others

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

  1. Executive summary
 
  1. U.S. Influenza Market Introduction
2.1. U.S. Influenza Market – Taxonomy 2.2. U.S. Influenza Market –Definitions 2.2.1. Drug Class Type 2.2.2. Route of Administration 2.2.3. Distribution Channel
  1. U.S. Influenza Market Dynamics
3.1. Drivers 3.2. Restraints 3.3. Opportunities/Unmet Needs of the Market 3.4. Trends 3.5. U.S. Influenza Market Dynamics – Factors Impact Analysis 3.6. U.S. Influenza Market – Regulations 3.6.1. U.S 3.6.2. Europe 3.6.3. Japan 3.6.4. China 3.7. U.S. Influenza Market – Product Innovations
  1. U.S. Influenza Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) 4.3. Market Oppurtunity Analysis
  1. U.S. Influenza Market, By Drug Class, 2015 – 2019 and Forecast, 2020 – 2026
5.1. Anti Viral Drugs 5.1.1. Zanamivir 5.1.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.1.1.3. Market Opportunity Analysis 5.1.2. Oseltamivir 5.1.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.1.2.3. Market Opportunity Analysis 5.1.3. Amantadine 5.1.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.1.3.3. Market Opportunity Analysis 5.1.4. Rimantadine 5.1.4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue,USD Mn) 5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.1.4.3. Market Opportunity Analysis 5.1.5. Others 5.1.5.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.1.5.3. Market Opportunity Analysis 5.2. Vaccines 5.2.1. Trivalent 5.2.1.1. Market Analysis, 2013 – 2019 and Forecast, 2019 – 2026 (Revenue, USD Mn) 5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.2.1.3. Market Opportunity Analysis 5.2.2. Quadrivalent 5.2.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 5.2.2.3. Market Opportunity Analysis
  1. U.S. Influenza Market Forecast, By Route of Administration, 2015 – 2019 and Forecast, 2020 – 2026
6.1. Oral 6.1.1. Market Analysis, 2013 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 6.1.3. Market Opportunity Analysis 6.2. Parenteral 6.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 6.2.3. Market Opportunity Analysis 6.3. Others 6.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 6.3.3. Market Opportunity Analysis
  1. U.S. Influenza Market Forecast, By Distribution Channel, 2015 – 2019 and Forecast, 2020 – 2026
7.1. Hospital pharmacies 7.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 7.1.3. Market Opportunity Analysis 7.2. Retail pharmacies 7.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 7.2.3. Market Opportunity Analysis 7.3. Others 7.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn) 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis 7.3.3. Market Opportunity Analysis
  1. U.S. Influenza Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
8.1. Drug Class Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 8.1.1. Anti-viral drugs 8.1.1.1. Zanamivir 8.1.1.2. Oseltamivir 8.1.1.3. Amantadine 8.1.1.4. Rimantadine 8.1.1.5. Others 8.1.1.6. Interferons 8.1.2. Vaccines 8.1.2.1. Trivalent 8.1.2.2. Quadrivalent 8.2. Route of Administration Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 8.2.1. Oral 8.2.2. Parenteral 8.2.3. Others 8.3. Distribution Channel Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Others 8.4. U.S. Influenza Market – Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel and Country, 2020 – 2026 8.5. U.S. Influenza Market Dynamics – Trends
  1. Competition Landscape
9.1. Strategic Dashboard of Top Market Players 9.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis) 9.2.1. AstraZeneca (UK) 9.2.2. F. Hoffmann-La Roche (Switzerland) 9.2.3. GlaxoSmithKline plc (UK) 9.2.4. Novartis AG (Switzerland) 9.2.5. Sanofi (France) 9.2.6. Seqirus (UK) 9.2.7. Protein Sciences Corporation (U.S.) 9.2.8. Emergent Biosolutions (U.S.) 9.2.9. BioCryst Pharmaceuticals.Inc (U.S.) 9.2.10. Alvogen (South Korea) 9.2.11. Medimmune Inc. (U.S.) 9.2.12. DynPort Vaccine Company, LLC. (U.S.) 9.2.13. Abbott Laboratories (U.S.)
  1. Research Methodology
 
  1. Key Assumptions and Acronyms
  • AstraZeneca (U.K.)
  • F. Hoffmann-La Roche (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Seqirus (U.K.)
  • Protein Sciences Corporation (U.S.)
  • Emergent Biosolutions (U.S.)
  • BioCryst Pharmaceuticals.Inc (U.S.)
  • Alvogen (South Korea)
  • Medimmune Inc. (U.S.)
  • DynPort Vaccine Company, LLC. (U.S.)
  • Abbott Laboratories (U.S.)